Rezolute, Inc. (RZLT) NASDAQ
4.00
+0.39(+10.80%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.00
+0.39(+10.80%)
Currency In USD
Address
201 Redwood Shores Parkway
Redwood City, CA 94065
United States of America (the)
Phone
650 206 4507
Website
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
January 14, 2013
| Name | Title | Pay | Year Born |
| Nevan Charles Elam | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board | 1.08M | 1967 |
| Daron G. Evans | Chief Financial & Business Officer | 699,209 | 1974 |
| Brian Kenneth Roberts | Chief Medical Officer | 767,526 | 1976 |
| Raj Agrawal | Vice President & Head of Ophthalmological Clinical Development | 0 | N/A |
| Robyn Sweinhart | Vice President & Head of Quality | 0 | N/A |
| Davelyn Eaves Hood | Director and Head of Scientific & Patient Affairs | 0 | N/A |
| Chris Milks | Vice President & Head of Finance | 0 | N/A |
| Melissa Quinn | Senior Director of People and Culture | 0 | N/A |
| Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management | 0 | N/A |
| Michael R. Deperro | Senior VP & Head of Operations | 0 | N/A |
| Erin O'Boyle | Senior Vice President & Head of Clinical Operations | 0 | N/A |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.